457654-55-6 Usage
Description
D,L-3-chlorophenylalanine Ethyl Ester Hydrochloride is a phenylalanine derivative that is an ethyl ester derivative of D,L-3-chlorophenylalanine. It is a chemical compound commonly used in research and drug development due to its potential therapeutic effects in treating various conditions.
Used in Pharmaceutical Research and Development:
D,L-3-chlorophenylalanine Ethyl Ester Hydrochloride is used as a research compound for its potential therapeutic effects in treating conditions such as depression, pain, and certain types of cancer. Its hydrochloride salt form enhances its stability and solubility in aqueous solutions, making it more suitable for use in research and pharmaceutical applications.
Used in Drug Development:
D,L-3-chlorophenylalanine Ethyl Ester Hydrochloride is used as a drug candidate in the development of new medications for the treatment of various conditions. Its precise mechanisms of action and potential side effects and toxicity are currently under investigation to determine its safety and efficacy for use in humans.
Check Digit Verification of cas no
The CAS Registry Mumber 457654-55-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,5,7,6,5 and 4 respectively; the second part has 2 digits, 5 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 457654-55:
(8*4)+(7*5)+(6*7)+(5*6)+(4*5)+(3*4)+(2*5)+(1*5)=186
186 % 10 = 6
So 457654-55-6 is a valid CAS Registry Number.
457654-55-6Relevant articles and documents
Anthranilic acid based CCK1 receptor antagonists: Preliminary investigation on their second "touch point"
Varnavas, Antonio,Lassiani, Lucia,Valenta, Valentina,Mennuni, Laura,Makovec, Francesco,Hadjipavlou-Litina, Dimitra
, p. 563 - 581 (2007/10/03)
In this phase of structure-affinity relationship study of VL-0395, a new anthranilic acid based CCK1 selective antagonist, we propose a series of unnatural aminoacidic derivatives. The result of this work is the identification of a new CCK ligand, which possesses an affinity (IC50 = 35 nm) one order of magnitude greater than the lead and, as a general rule, it points out how the hypothesized receptorial pocket which accommodates the Phe residue allows much more structural modification than that interacting with the N-terminal group. Hence, the modification of the C-terminal pharmacophoric group of our lead VL-0395 can not only enhance the affinity of anthranilic acid derivatives but can modulate the selectivity for one CCK receptor subtype or afford mixed antagonists.
